Safety and Efficacy Study of ESBA1008 Versus LUCENTIS for the Treatment of Exudative Age-Related Macular Degeneration

Trial Profile

Safety and Efficacy Study of ESBA1008 Versus LUCENTIS for the Treatment of Exudative Age-Related Macular Degeneration

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 May 2016

At a glance

  • Drugs Brolucizumab (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus First in man; Proof of concept; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 04 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top